

Article

Not peer-reviewed version

Spread of Extended-Spectrum- β -Lactamase-Producing Pathogenic *Escherichia coli* Clonal Complex 10 in the Republic of Korea

Jungsun Park , Eunkyung Shin , Joohyun Han , Wooju Kang , Jaeil Yoo , Jung-sik Yoo , Dong-Hyun Roh ,
[Junyoung Kim](#) *

Posted Date: 31 August 2023

doi: 10.20944/preprints202308.2095.v1

Keywords: ESBL; pathogenic *E. coli*; Clonal complex; CTX-M



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article

Spread of Extended-Spectrum- β -Lactamase-Producing Pathogenic *Escherichia coli* Clonal Complex 10 in the Republic of Korea

Jungsun Park ¹, Eunkyung Shin ¹, Joohyun Han ¹, Wooju Kang ¹, Jaeil Yoo ¹, Jung-sik Yoo ², Dong-Hyun Roh ³ and Junyoung Kim ¹

¹ Division of Bacterial Diseases, Bureau of Infectious Disease Diagnosis Control, Korea Disease Control and Prevention Agency, Chungcheongbuk-do, Republic of Korea

² Division of Antimicrobial Resistance Research, Center for Infectious Disease Research, Korea National Institute of Health, Chungcheongbuk-do, Republic of Korea

³ Department of Biological Sciences and Biotechnology, Chungbuk National University, Cheongju, Republic of Korea

* Correspondence: author: Junyoung Kim; Division of Bacterial Diseases, Bureau of Infectious Disease Diagnosis Control, Korea Disease Control and Prevention Agency, Chungcheongbuk-do, Republic of Korea; Tel.: +82-43-719-8116; Fax: +82-43-719-8109; E-mail: jun49@hanmail.net

Abstract: ESBL-producing *E. coli* is a growing public problem in healthcare settings and the community. Between 2009 and 2018, a total of 187 ESBL-producing pathogenic *E. coli* isolates were confirmed, and clonal complex (CC) 10 was the predominant clone. This study aimed to characterize ESBL-producing pathogenic *E. coli* CC10 strains obtained from diarrheal patients to improve the understanding of CC10 distribution in the Republic of Korea. A total of 57 CC10 strains were selected for molecular characterizations, such as the identification of serotype, antibiotic resistance genes, genetic environments, plasmid profiles, and the genetic correlation between CC10 strains. In the CC10 isolates, the most prevalent serotype was O25:H16, followed by O6:H16. ESBL genes were identified as *bla*_{CTX-M}, and the most dominant ESBL gene was *bla*_{CTX-M-15} (56%) and *bla*_{CTX-M-14} (30%). Most *bla*_{CTX-M} genes were located on plasmids, and these plasmid profiles were confirmed as IncB/O/K/Z, IncF, IncI1 and IncX1. The mobile elements located up-and down-stream mainly included *ISEcp1* (complete or incomplete) and *IS903* or *orf477* were found, respectively. Phylogenetic analysis showed that the CC10 strains were genetically diverse and divided into several distinct lineages. In this study, we found that CC10 ESBL-producing pathogenic *E. coli* has been steadily isolated; particularly, CTX-M-15-producing *E. coli* O25:H16 isolates were the major type related with distribution in CC10 clones during the last decade. Identification of ESBL-producing pathogenic *E. coli* CC10 isolates highlights the possibility of the emergence of resistant isolates with epidemic potential within this CC. Therefore, continuous monitoring will be conducted to prevent further spread of resistant ESBL-producing *E. coli* CC10 strains.

Keywords: ESBL; pathogenic *E. coli*; clonal complex; CTX-M

1. Introduction

Extended-spectrum cephalosporin resistance is a major threat worldwide, as the cephalosporins are often used as first-line antimicrobial agents for treating infections caused by Gram-negative bacteria [1,2]. Cephalosporin-resistant bacteria produce enzymes called extended-spectrum beta-lactamases (ESBLs). ESBL enzymes hydrolyze antibiotics, including penicillins and cephalosporins, making these drugs ineffective in treating infections [3].

ESBL-producing *Enterobacteriaceae* are rising a major public problem in healthcare settings and the community. In 2017, there were an estimated 197,400 cases among hospitalized patients and 9,100 estimated deaths in the United States [1]. Among these *Enterobacteriaceae*, *E. coli* is one of the primary pathogens of antimicrobial-resistant clinical infections [4]. The emergence of *E. coli* strains resistant to extended-spectrum cephalosporins was observed after the 2000s and continuously reported at present.

To understand the genetic diversity of *E. coli*, multilocus sequence typing has been most frequently used [5]. The prevalence of ESBL-producing *E. coli*, particularly sequencing type (ST) 131, has been reported as the predominant sequence type [6]. Following a study from Europe, the incidence of ESBL-producing *E. coli* ST131 has been reported to be 20% in four European hospitals [7]. Also, *E. coli* ST131 isolates have been reported in Korea. ST131 is the predominant clone among ESBL-producing isolates in community and healthcare settings in Korea [8]. Much of the literature focuses on an occurrence of clonal related antimicrobial-resistant bacteria is expected to contribute to understanding of transmission their pathway. Therefore, it is necessary to analyze the clonal diversity of the antimicrobial resistant strains.

The Korea Disease Control and Prevention Agency (KDCA) has collected and tested pathogenic *E. coli* isolates from patients with diarrhea to monitor antimicrobial resistance profiles. Between 2009 and 2018, a total of 187 third-generation cephalosporin-resistant pathogenic *E. coli* isolates were confirmed and the clonal complex (CC) 10 was the predominant clones. The objective of this study was to characterize ESBL-producing pathogenic *E. coli* CC10 strains obtained from diarrheal patients in recent decades, to improve the understanding of CC10 distribution in Korea and the world.

2. Results

2.1. Serotyping

The 57 pathogenic *E. coli* CC10 isolates were obtained from 16 regions in the Republic of Korea. The strains belonged to 12 O serogroups and expressed 8 different H antigens. The O serotypes were O25 (n=22), O6 (n=10), O101 (n=5), O99 (n=5), and O3 (n=3). The more common H serotypes were H16 (n=35), H33 (n=6), H2 (n=5), H10 (n=5) and H30 (n=3). The most prevalent serotype was O25:H16 (38.9%, 21/57), followed by O6:H16 (19.6%, 10/57), O99:H10 (9.8%, 5/57) and O101:H33 (9.8%, 5/57) (Figure 1). *In silico* FimH typing revealed 11 types of FimH (Figure 3.2). Of the total CC10, 16 (31.4%), 9 (17.7%), 8 (15.7%), 5 (9.8%), 4 (7.8%), and 1(1.9%) were positive for FimH198, FimH54, FimH23, FimH30, FimH24, and FimH1194, respectively.

Strain ID	Year	ST	Pathotype	Serotype	Resistance genes																				Replicon type							
					Beta-lactam										Fluoroquinolone				Tetracycline		Aminoglycoside		Macrolide			Chloramphenicol						
					bla _{CTXA3}	bla _{CTXA4-14}	bla _{CTXA4-15}	bla _{CTXA4-27}	bla _{CTXA4-55}	bla _{CTXA30}	bla _{CTXA-30}	bla _{CTXA-28}	bla _{CTXA-41}	bla _{CTXA308}	bla _{CTXA307}	gyrA(S83L)	gyrA(S83A)	gyrA(D87 G)	gyrA(D87N)	qnrS1	qnrB4	tet(A)	aac(3)-Ia	aac(6)-Ib-cr	aac(3)-IId	aph(3)-Ib	aph(6)-Id	mph(A)	catB3	floR	cmfA1	
20090041	2009	34	EPEC	O101:H33																												F
20110030	2011	34	EPEC	O101:H33																												B/O/K/Z
20110125	2011	4	ETEC	O6:H16																												X1
20110218	2011	34	EAEC	O92:H33																												
20110252	2011	4	ETEC	O6:H16																												X1
20110253	2011	1312	ETEC	O25:H16																												B/O/K/Z
20110462	2011	1312	ETEC	O25:H16																												B/O/K/Z
20110765	2011	1312	EPEC	O25:H16																												
201112025	2011	218	EPEC	O159:H34																												I1
201112155	2011	1312	ETEC	O25:H16																												
201112395	2012	4	ETEC	O6:H16																												
20120209	2012	10	EPEC	O127:H16																												
20121544	2012	4	ETEC	O6:H16																												
20121813	2012	1491	ETEC	O25:H16																												I1
20122124	2012	1491	ETEC	O25:H16																												I1
20122570	2012	1312	ETEC	O4:H16																												F
20123617	2012	34	EPEC	O101:H33																												F
20123618	2013	34	EAEC	O99:H10																												B/O/K/Z
20130502	2013	34	EAEC	O99:H10																												I1
20130509	2013	10	EAEC	O86:H2																												F
20130569	2013	10	EAEC	O3:H2																												F
20132718	2014	10	EAEC	O3:H2																												F
20134849	2014	10	EPEC	H16																												I1
20140044	2014	10	EAEC	O21:H2																												F
20140220	2014	34	EPEC	O101:H33																												I1
20140370	2014	34	EAEC	O99:H10																												B/O/K/Z
20140384	2014	34	EAEC	O99:H10																												B/O/K/Z
20140777	2014	34	EAEC	O99:H10																												F
20143336	2015	34	EPEC	O101:H33																												
20145955	2015	1312	ETEC	O25:H16																												
20150271	2015	752	EPEC	ONT																												
20150375	2015	1491	EPEC	O25:H16																												B/O/K/Z
20150390	2016	752	EPEC	ONT:H30																												
20153838	2016	752	EPEC	ONT:H30																												
20160275	2016	6955	ETEC	O6:H16																												F
20161813	2016	6955	ETEC	O6:H16																												F
20170132	2017	1312	ETEC	O25:H16																												B/O/K/Z
20170416	2017	10	EPEC	O51:H40																												I1
20172464	2017	1491	ETEC	O25:H16																												B/O/K/Z
20172480	2017	1491	ETEC	O25:H16																												B/O/K/Z
20172500	2017	1491	ETEC	O25:H16																												B/O/K/Z
20172611	2017	1491	ETEC	O25:H16																												B/O/K/Z
20172624	2017	1491	ETEC	O25:H16																												B/O/K/Z
20172646	2017	1491	ETEC	O25:H16																												B/O/K/Z
20180444	2018	4	ETEC	O6:H16																												
20180595	2018	1491	ETEC	O25:H16																												B/O/K/Z
20181199	2018	1491	EPEC	O25:H16																												

Figure 1. Heatmap shows sample ID, year of isolation, ST, Pathotype, Serotype, AMR profile and plasmid replicon type.

2.2. Distribution of genomic determinants of antimicrobial resistance

A total of 34 antimicrobial resistance genes/mutations were detected, involving six classes of antimicrobial agents, including beta-lactam (18 genes), fluoroquinolone (two genes and four mutations), tetracycline (one gene), aminoglycoside (five genes), macrolide (one gene) and chloramphenicol (three genes) (Figure 1).

Beta-lactam resistance genes were detected in all CC10 isolates; *bla_{CTX-M-15}* and *bla_{CTX-M-14}* were most prevalent and were found in 26 (51%) and 15 (30%) isolates, respectively. Also, 17 strains carried *bla_{TEM}* genes. Fluoroquinolone resistance genes/mutations were present in all isolates, of which quinolone resistance-determining regions (QRDRs) of *gyrA* genes mutation and plasmid-mediated quinolone resistance (PMQR) gene (*qnrS1* and *qnrB4*) were found in 32 (62.7%) and 23 (45.1%) isolates, respectively. Mutations in the *gyrA* gene were observed at codons 83 and 87, producing the single-residue substitutions S83L, S83A, D87G and D87N. Multiple fluoroquinolone resistance associated mutations were detected in two isolates, specifically, double mutations in *gyrA* (S83L with D87G or D87N). Tetracycline resistance was identified in 22 (43.2%) isolates and macrolide resistance was confirmed in 13 (25.5%) isolates of genotypes *tet(A)* and *mph(A)*, respectively. Aminoglycoside resistance genes were harbored by 10 isolates (19.6%), including *aac(3)-Iia*, *aac(6')-Ib-cr*, *aac(3)-Iid*, *aph(3'')-Ib* and *aph(6)-Id*. These isolates carried one or two resistance genes. Chloramphenicol resistance genes were detected in 5 (9.8%) isolates that were *catB3*, *floR* and *cmlA1*.

2.3. Transmission of *bla* gene

Characterization of *bla_{CTX-M}* plasmids was performed to better understand the horizontal transfer of *bla_{CTX-M}* using conjugation. CC10 strains capable of horizontal transfer through conjugation were identified as 82.5% (45/57) of the total. Twenty-three isolates carried an IncB/O/K/Z plasmid, twelve isolates carried an IncF-type plasmid, eight isolates carried an IncI1 plasmid, and two carried an IncX1 plasmid.

2.4. Analysis of the regions surrounding *bla_{CTX-M}* genes

Four different structures [type I (10 isolates), type II (23 isolates), type III (3 Isolates) and type IV (9 isolates)] were identified regarding the genetic elements of *bla_{CTX-M}* (Figure 2).




Figure 2. Genetic environment of *bla_{CTX-M}* gene in this study. Type I architecture (*ISEcp1-bla_{CTX-M}-ORF477*) was found in 10 isolates; Type II architecture (*IR-R-bla_{CTX-M}-ORF477*) was found in 23 isolates; Type III architecture (Δ *ISEcp1-bla_{CTX-M}-IS903*) was found in 3 isolates; Type IV architecture (*ISEcp1-bla_{CTX-M}-IS903*) was found in 9 isolates.

Type I genetic structure was found in 10 isolates producing *bla_{CTX-M}* with *ISEcp1-bla_{CTX-M}-orf477* genetic structures. Type II genetic structure was most common and identified in 23 isolates. Analysis of the region flanking *bla_{CTX-M}* revealed an *orf477* downstream sequence with a spacer region between the inverted repeat (IR) sequences of *ISEcp1* upstream. These genetic structures belong to the CTX-M-I group, such as *bla_{CTX-M-3}*, *-15* and *-55* possessing isolates. However, Type III genetic structure was identified in three isolates that had a different genetic element flanking *bla_{CTX-M}*, *ISEcp1* upstream and downstream of the *IS903* (*IR-ISEcp1-bla_{CTX-M}-IS903*). Three isolates have type IV genetic structure, with *ISEcp1-bla_{CTX-M}-IS903* as a transposable element.

2.5. Whole-genome SNPs-based phylogeny of CC10

Phylogenetic analysis was performed with 265 genomes of *E. coli* strains belonging to the international CC10, a whole-genome SNP phylogeny was generated using *E. coli* K12-MG1655 as a reference (Figure 3). To better understand the global population structure of *E. coli* CC10, we have identified a genome alignment in which 14,260 SNPs were identified. Phylogeny analysis of 57 clinical pathogenic *E. coli* isolates in this study identified several distinct lineages, which comprised ST4, ST10, ST34, ST752, ST1312, and ST1491. There was no observed substantial clustering related to location or time of sampling during this study period.




Figure 3. Whole genome SNP-derived phylogenetic tree of the CC10 isolates in a global context. The tree includes 265 international *E. coli* CC10 sequences, including the reference sequence of *E. coli* K-12 MG1655. The diagram depicts a phylogenetic tree with a genome alignment of 14,260 SNPs for 265 globally CC10 strains, including all publicly available isolates from Enterobase. The node color represents the source of isolations, the colored ring around the tree indicated the country of isolates.

There was observed substantial clustering related to CC10 isolated in the Republic of Korea from 27 reference strains. ST1312carrying-*bla*_{CTX-M-15-1} and ST1312carrying-*bla*_{CTX-M-15-2}, isolated from river in Sweden in 2013, were closely related ranging from 100 to 109 SNP differences within this study strains (20112155 and 20170132) [9]. These isolates had the O25:H16 serotype and common resistance genes, including *sul1*, *dfrA14*, *tet(A)* and *bla*_{CTX-M-15}.

Five isolates (20121544, 20180444, 20181364, 20181484, 20181747) from this study were similar to isolates collected from patients in China between 2017 and 2019 (6 to 91 SNP differences); they also harbored *bla*_{CTX-M-15} or *bla*_{CTX-M-14} and had mutations in quinolone resistance-determining regions (E18090, E18013, E19033, E19059, E15052, E20033, E17113, E19010, E17090) [10].

Five isolates (20123618, 20130502, 20140370, 20140384, 20140777) from this study were related to isolates 1512689, 1545515, 3-6-R5 from patients in the United Kingdom and Australia, with SNP differences ranging from 39 to 195. One isolate (287717) from the United Kingdom in 2016 was

genetically similar to two isolates from this study (20160275, 20161813), with the same genetic determinants, plasmids, and serotype, with SNP differences ranging from 33 and 46 [11]. Two clinical isolates from China in 2017 (CN-202-F, CN-263-D) carried same antimicrobial resistance genes, mutations, and plasmids as present in similar human isolates (20182244, 20180595, 20181199, 20182201, 20182274, 20183083, 20182759) in this study (54 to 58 SNP differences).

3. Discussion

ESBL-producing pathogenic *E. coli* sequence types are extremely genetically diverse in the past decade. During this period, CC10 was the most prominent types, comprising 57 isolates with 9 different STs. In this study, compared the CC10 of ESBL-producing clinical *E. coli* isolates derived from human in order to describe their characteristics.

All strains in association with ESBL showed high multidrug-resistant (MDR) occurrence. Although resistance rate was to tetracycline, followed by nalidixic acid, azithromycin, ciprofloxacin and trimethoprim/sulfamethoxazole. Most MDR in *E. coli* associated with ESBLs has become a serious problem in public health because of dissemination of ESBL genes. It has posed a major threat to treatment of bacterial infections [12].

In CC10 isolates, the incidence of CTX-M was highest, at 98.4% of the total and most dominant ESBL gene was *bla*_{CTX-M-15} (56%, 32/57). Majority of CTX-M-15 producing isolates have common features in that they belonging to serotype O25:H16 (53%, 17/32). Our finding indicated the common features that the CTX-M-15 producing *E. coli* O25:H16 in CC10 isolates presented to have emerged and expanded in the distribution during the last decade. These strains were sporadically isolated from 10 regions but clonally related with less than 70 SNPs separating them.

Also, our study contributes to the highlighting that plasmid acquisition is probably an important mechanism for the dissemination of CTX-M-producing pathogenic *E. coli*. Resistance to third generation cephalosporins is caused by the acquisition of ESBL genes, primarily *bla*_{CTX-M} gene [13]. Conjugation experiments were performed to confirm the horizontal transmission of plasmid-borne *bla*_{CTX-M} genes and identified such transfer in 78.9 % (45/57) CC10 isolates. This suggested that the high incidence of CC10 isolates is caused by horizontal transfer of ESBL genes between bacteria seems as the best way of transmission. The predominant genotype of plasmid-mediated *bla*_{CTX-M} gene were CTX-M-15 (64.4%, 29/45) and CTX-M-14 (22.2%, 10/45). The mobile elements located upstream of *bla*_{CTX-M-14} and -15 gene mainly included *ISEcp1* (complete or incomplete). Downstream of *bla*_{CTX-M-14} and -15 genes *IS903* and *orf477* was found, respectively.

Here, we found the persistent occurrence of *bla*_{CTX-M-15} gene and observed the highest proportion in 2018. The *bla*_{CTX-M-15} gene was known as the most widely distributed *bla*_{CTX-M} gene in the world [14]. Previous studies in the Republic of Korea have indicated that *bla*_{CTX-M-15}-harboring *E. coli* have isolated from raw vegetables and food animals in 2018, respectively [15,16]. It suggested *bla*_{CTX-M-15}-producing *E. coli* may circulate among food, food animals, and humans that might contribute to the acquisition of resistance.

To compare with the WGS-based population structure of our isolates in the context of the international CC10 lineages, five isolates is highly similar that of ETEC isolates from diarrhoea patients in China collected from 2017 to 2019 [10]. Among five isolates, one isolate was collected in 2012, other four isolates were isolated in 2018. SNP analysis of those isolates found 6 to 91 SNPs, thus indicating a close relationship among the isolates, even though they were identified from distinct countries. These isolates were possessed *bla*_{CTX-M-15} or *bla*_{CTX-M-14} genes, genetic determinants, plasmids, and serotype. This study from China described *E. coli* isolated from patients, suggesting that spread from unknown source could possibly disseminate the presence of the clone. These results revealed that the circulating CC10 from Republic of Korea, as well as in other countries were genetically close related, which are suggesting expansion of global or endemic population.

Based on these observations, CC10 may become the most important strain in the Republic of Korea. During last decade, CC10 of ESBL-producing pathogenic *E. coli* have steadily isolated, especially, it has almost doubled recently. This result suggested that CC10 clone is emerging as the one of the important clones in human clinical cases for its association with third cephalosporins

resistance. Several previous studies reported that *E. coli* CC10 have a predominant clonal group associated with extraintestinal disease in both animals and humans [17,18]. Some regional monitoring investigations from Italy, Spain, and Portugal showed that CC10 strains from humans, bird, and swine were associated with multiple CTX-M-type genes [19–21].

Pathogenic *E. coli* has emerged as a major cause of food- and water-borne diseases in Korea. Currently, most of the data on ESBL-producing pathogenic *E. coli* CC10 are from studies conducted in the Republic of Korea and may reflect a local situation. Therefore, the necessary data for the national management of pathogenic *E. coli* infections and the management of related fields were secured. Future studies surveying for the presence of CC10 clone will provide information as to whether this is the case in other countries worldwide.

4. Materials and methods

4.1. Background

A total of 187 third-generation cephalosporin-resistant *E. coli* isolates were collected by the national surveillance system (Enter-Net and Pulse-Net Korea) between 2009 and 2018. These isolates were collected from stool or rectal swabs from patients with gastrointestinal symptoms, including diarrhea, abdominal pain, vomiting, nausea, and fever. Initial investigation was performed to determine sequence types (STs) and clonal complexes (CCs) based on seven housekeeping genes (https://enterobase.warwick.ac.uk/species/ecoli/allele_st_search) and the 187 resistance isolates were grouped into 77 STs. CC10 was the most prevalent clonal complex, comprising 57 (31.4%, 57/187) isolates with 9 different STs (4, 10, 34, 218, 752, 1201, 1312, 1491, 6955). 57 CC10 strains were selected for analysis of molecular characterization such as serotype, other antibiotic resistance genes, genetic environments, plasmid profiles and genetic correlation between the CC10 strains isolated in the Republic of Korea.

4.2. Whole genome sequencing (WGS)

Genomic DNA was isolated using a Blood and Tissue kit (Qiagen, Stockach, Germany) according to the manufacturer's protocol. The purified total DNA quality was measured using a NanoDrop 2000 spectrophotometer (Thermo Fisher, DE, USA). The concentration was determined with a Qubit 4 fluorometer using a high-sensitivity kit (Invitrogen, CA, USA). Library fragment lengths were assessed through the use of a Bioanalyzer TapeStation with DNA 1000 kit (Agilent Technologies, Inc., CA, USA). A paired-end sequencing library was constructed with an Illumina DNA prep kit (Illumina, San Diego, CA, USA) following the manufacturer's protocol. Sequencing was performed using a 500-cycle (2×250-bp paired-end) MiSeq reagent kit version 2 with an MiSeq sequencer.

4.3. Data analysis and molecular characterization

Raw sequences generated by Illumina MiSeq were quality filtered using FastQC, with average quality set at Q30. Raw reads from the Illumina sequencing were quality trimmed using CLC genomic workbench 22 (Qiagen, Hilden, Germany). Contigs of genomic sequences were assembled with a minimum size threshold of 200 bp using the de novo assembler in CLC genomic workbench 22 (Qiagen, Hilden, Germany). Assembled sequences were analyzed for antimicrobial resistance genes (ResFinder 4.1), plasmid replicon types (PlasmidFinder 2.1), serotypes (SerotypeFinder 2.0), and *fimH* and *fumC* (CHTyper 1.0) using web tools available from the Center for Genomic Epidemiology (CGE) (<http://www.genomicepidemiology.org/>) [22]. Single-nucleotide polymorphisms (SNPs) were identified using CSI phylogeny 1.4 (<https://cge.cbs.dtu.dk/services/CSIPhylogeny/>) by comparison with *E. coli* K-12 MG1655 (GenBank accession no. U00096) as a reference strain with 265 *E. coli* genomes with the same sequence type (CC10), retrieved from Enterobase (listed in Supplementary Table S1). Selection of SNPs used default parameters in CSI Phylogeny, which included a minimum distance of 10 bp between SNPs, a minimum of 10% of the average depth, mapping quality above 25, and SNP quality above 30. All insertions and deletions (INDELs) were excluded.

4.4. Plasmid transfer by bacterial conjugation

For strains with results for cefotaxime resistance was examined by conjugation experiments using azide-resistant *E. coli* J53 as recipient strain to confirm the transmission capacity of the *bla* genes [23]. Transconjugants were selected on MacConkey agar plates (Difco, USA) supplemented with cefotaxime (1mg/L) and sodium azide (200mg/L). The acquisition of the *bla* gene was confirmed by PCR and sequencing analysis.

4.5. Nucleotide sequence accession numbers

The whole-genome sequences of these strains were deposited with the NCBI Sequence Read Archive (SRA) under the Bio-Project PRJNA628558.

5. Conclusions

CC10 of ESBL-producing pathogenic *E. coli* isolates have been a steady increase for the past decade. Presently, ESBL-producing pathogenic *E. coli* CC10 may become the most important strain in the Republic of Korea. Among these isolates, CTX-M-15-producing pathogenic *E. coli* O25:H16 isolates were the major type in CC10 clones. There have been a few studies that address this issue in CC10 isolates both in the Republic of Korea and in other countries. Identification of CC10 isolates highlights the possibility of the emergence of resistant isolates with epidemic potential within this CC. Therefore, continuous monitoring will be required to prevent further spread of resistant ESBL-producing *E. coli* CC10 strains.

Author Contributions: JP and JuK conceived of the study and participated in its design and draft the manuscript. ES and JH collected samples and identified isolates. JP carried out the experiments and analyzed the data. JY, JsY and DHR contributed to experiment conception. All authors contributed to the article and approved the submitted version.

Funding: This work was supported by a grant from the Korea Disease Control and Prevention Agency (grant number 4847-311-210).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: All data generated for this study are contained within the article.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. CDC ANTIBIOTIC RESISTANCE THREATS IN THE UNITED STATES, 2019. **2019**, *10*, doi:10.1186/s13756-020-00872-w.
2. Watkins, R.R.; Bonomo, R.A. Overview: Global and Local Impact of Antibiotic Resistance. *Infectious disease clinics of North America* **2016**, *30*, 313–322, doi:10.1016/j.idc.2016.02.001.
3. Shaikh, S.; Fatima, J.; Shakil, S.; Rizvi, S.M.D.; Kamal, M.A. Antibiotic Resistance and Extended Spectrum Beta-Lactamases: Types, Epidemiology and Treatment. *Saudi journal of biological sciences* **2015**, *22*, 90–101, doi:10.1016/j.sjbs.2014.08.002.
4. Malik, F.; Figueras, A. Continuous Rise in Cephalosporin and Fluoroquinolone Consumption in Pakistan: A 5 Year Analysis (2014–18). *JAC-Antimicrobial Resistance* **2019**, *1*, 1–4, doi:10.1093/jacamr/dlz063.
5. Yu, F.; Chen, X.; Zheng, S.; Han, D.; Wang, Y.; Wang, R.; Wang, B.; Chen, Y. Prevalence and Genetic Diversity of Human Diarrheagenic Escherichia Coli Isolates by Multilocus Sequence Typing. *International Journal of Infectious Diseases* **2018**, *67*, 7–13, doi:10.1016/j.ijid.2017.11.025.
6. Zhong, Y.; Guo, S.; Seow, K.L.G.; Ming, G.O.H.; Schlundt, J. Characterization of Extended-Spectrum Beta-Lactamase-Producing Escherichia Coli Isolates from Jurong Lake, Singapore with Whole-Genome-Sequencing. *International journal of environmental research and public health* **2021**, *18*, doi:10.3390/ijerph18030937.

7. Merino, I.; Hernández-García, M.; Turrientes, M.-C.; Pérez-Viso, B.; López-Fresneña, N.; Diaz-Agero, C.; Maechler, F.; Fankhauser-Rodriguez, C.; Kola, A.; Schrenzel, J.; et al. Emergence of ESBL-Producing *Escherichia Coli* ST131-C1-M27 Clade Colonizing Patients in Europe. *The Journal of antimicrobial chemotherapy* **2018**, *73*, 2973–2980, doi:10.1093/jac/dky296.
8. Park, S.H.; Byun, J.-H.; Choi, S.-M.; Lee, D.-G.; Kim, S.-H.; Kwon, J.-C.; Park, C.; Choi, J.-H.; Yoo, J.-H. Molecular Epidemiology of Extended-Spectrum β -Lactamase-Producing *Escherichia Coli* in the Community and Hospital in Korea: Emergence of ST131 Producing CTX-M-15. *BMC Infectious Diseases* **2012**, *12*, 149, doi:10.1186/1471-2334-12-149.
9. Fagerström, A.; Mölling, P.; Khan, F.A.; Sundqvist, M.; Jass, J.; Söderquist, B. Comparative Distribution of Extended-Spectrum Beta-Lactamase-Producing *Escherichia Coli* from Urine Infections and Environmental Waters. *PloS one* **2019**, *14*, e0224861, doi:10.1371/journal.pone.0224861.
10. Yang, C.; Li, Y.; Zuo, L.; Jiang, M.; Zhang, X.; Xie, L.; Luo, M.; She, Y.; Wang, L.; Jiang, Y.; et al. Genomic Epidemiology and Antimicrobial Susceptibility Profile of Enterotoxigenic *Escherichia Coli* From Outpatients With Diarrhea in Shenzhen, China, 2015-2020. *Frontiers in microbiology* **2021**, *12*, 732068, doi:10.3389/fmicb.2021.732068.
11. Greig, D.R.; Jenkins, C.; Gharbia, S.; Dallman, T.J. Comparison of Single-Nucleotide Variants Identified by Illumina and Oxford Nanopore Technologies in the Context of a Potential Outbreak of Shiga Toxin-Producing *Escherichia Coli*. *GigaScience* **2019**, *8*, doi:10.1093/gigascience/giz104.
12. Xu, Y.; Sun, H.; Bai, X.; Fu, S.; Fan, R.; Xiong, Y. Occurrence of Multidrug-Resistant and ESBL-Producing Atypical Enteropathogenic *Escherichia Coli* in China. *Gut Pathogens* **2018**, *10*, 8, doi:10.1186/s13099-018-0234-0.
13. Bartoloni, A.; Pallecchi, L.; Riccobono, E.; Mantella, A.; Magnelli, D.; Di Maggio, T.; Villagran, A.L.; Lara, Y.; Saavedra, C.; Strohmeyer, M.; et al. Relentless Increase of Resistance to Fluoroquinolones and Expanded-Spectrum Cephalosporins in *Escherichia Coli*: 20 Years of Surveillance in Resource-Limited Settings from Latin America. *Clinical Microbiology and Infection* **2013**, *19*, 356–361, doi:https://doi.org/10.1111/j.1469-0691.2012.03807.x.
14. Bevan, E.R.; Jones, A.M.; Hawkey, P.M. Global Epidemiology of CTX-M β -Lactamases: Temporal and Geographical Shifts in Genotype. *The Journal of antimicrobial chemotherapy* **2017**, *72*, 2145–2155, doi:10.1093/jac/dkx146.
15. Song, J.; Oh, S.-S.; Kim, J.; Shin, J. Extended-Spectrum β -Lactamase-Producing *Escherichia Coli* Isolated from Raw Vegetables in South Korea. *Scientific Reports* **2020**, *10*, 19721, doi:10.1038/s41598-020-76890-w.
16. Song, J.; Oh, S.-S.; Kim, J.; Park, S.; Shin, J. Clinically Relevant Extended-Spectrum β -Lactamase-Producing *Escherichia Coli* Isolates From Food Animals in South Korea. *Frontiers in Microbiology* **2020**, *11*.
17. Usein, C.-R.; Papagheorghe, R.; Oprea, M.; Condei, M.; Străuț, M. Molecular Characterization of Bacteremic *Escherichia Coli* Isolates in Romania. *Folia microbiologica* **2016**, *61*, 221–226, doi:10.1007/s12223-015-0427-6.
18. Giufre, M.; Graziani, C.; Accogli, M.; Luzzi, I.; Busani, L.; Cerquetti, M. *Escherichia Coli* of Human and Avian Origin: Detection of Clonal Groups Associated with Fluoroquinolone and Multidrug Resistance in Italy. *The Journal of antimicrobial chemotherapy* **2012**, *67*, 860–867, doi:10.1093/jac/dkr565.
19. Ramos, S.; Silva, N.; Dias, D.; Sousa, M.; Capelo-Martinez, J.L.; Brito, F.; Caniça, M.; Igrejas, G.; Poeta, P. Clonal Diversity of ESBL-Producing *Escherichia Coli* in Pigs at Slaughter Level in Portugal. *Foodborne pathogens and disease* **2013**, *10*, 74–79, doi:10.1089/fpd.2012.1173.
20. Okeke, I.N.; Wallace-Gadsden, F.; Simons, H.R.; Matthews, N.; Labar, A.S.; Hwang, J.; Wain, J. Multi-Locus Sequence Typing of Enteropathogenic *Escherichia Coli* Isolates from Nigerian Children Uncovers Multiple Lineages. *PLOS ONE* **2010**, *5*, e14093.
21. Oteo, J.; Pérez-Vázquez, M.; Campos, J. Extended-Spectrum Beta-Lactamase Producing *Escherichia Coli*: Changing Epidemiology and Clinical Impact. *Current Opinion in Infectious Diseases* **2010**, *23*, 320–326, doi:10.1097/QCO.0b013e3283398dc1.
22. Camacho, C.; Coulouris, G.; Avagyan, V.; Ma, N.; Papadopoulos, J.; Bealer, K.; Madden, T.L. BLAST+: Architecture and Applications. *BMC Bioinformatics* **2009**, *10*, 421, doi:10.1186/1471-2105-10-421.
23. Kim, J.S.; Kim, J.; Jeon, S.E.; Kim, S.J.; Kim, N.O.; Hong, S.; Kang, Y.H.; Han, S.; Chung, G.T. Complete Nucleotide Sequence of the IncI1 Plasmid PSH4469 Encoding CTX-M-15 Extended-Spectrum β -Lactamase in a Clinical Isolate of *Shigella Sonnei* from an Outbreak in the Republic of Korea. *International Journal of Antimicrobial Agents* **2014**, *44*, 533–537, doi:10.1016/j.ijantimicag.2014.08.007.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.